| Budget Amount *help |
¥160,290,000 (Direct Cost: ¥123,300,000、Indirect Cost: ¥36,990,000)
Fiscal Year 2020: ¥28,080,000 (Direct Cost: ¥21,600,000、Indirect Cost: ¥6,480,000)
Fiscal Year 2019: ¥29,250,000 (Direct Cost: ¥22,500,000、Indirect Cost: ¥6,750,000)
Fiscal Year 2018: ¥26,520,000 (Direct Cost: ¥20,400,000、Indirect Cost: ¥6,120,000)
Fiscal Year 2017: ¥31,070,000 (Direct Cost: ¥23,900,000、Indirect Cost: ¥7,170,000)
Fiscal Year 2016: ¥45,370,000 (Direct Cost: ¥34,900,000、Indirect Cost: ¥10,470,000)
|
|---|
| Outline of Final Research Achievements |
Small molecule drugs, which exhibit biological activity through key-hole interactions, are not good at multi-point molecular recognition of target proteins bearing wide recognition regions. In contrast, mid-molecular drugs are considered more effective and powerful in protein-protein interactions. These "large and medium molecules," which are generally composed of amino acids and sugars, are still not easy to synthesize chemically in large quantities and at low cost due to the size and complexity of their molecular structures. Therefore, we have developed various "artificial organocatalysts" necessary for the efficient synthesis of peptides, oligosaccharides, and glycopeptides composed of natural and unnatural amino acids and monosaccharides. We have established several fundamental technologies for the precision synthesis of new-modality drugs "large and medium-sized molecules", for which demand will increase in the future.
|
